- Home
- FISI vs PSNL Comparison
FISI vs PSNL Comparison
Compare FISI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FISI
- PSNL
- Stock Information
- Founded
- FISI 1817
- PSNL 2011
- Country
- FISI United States
- PSNL United States
- Employees
- FISI 598
- PSNL N/A
- Industry
- FISI Major Banks
- PSNL Medical Specialities
- Sector
- FISI Finance
- PSNL Health Care
- Exchange
- FISI Nasdaq
- PSNL Nasdaq
- Market Cap
- FISI 554.8M
- PSNL 562.6M
- IPO Year
- FISI 1999
- PSNL 2019
- Fundamental
- Price
- FISI $27.47
- PSNL $6.45
- Analyst Decision
- FISI Buy
- PSNL Strong Buy
- Analyst Count
- FISI 3
- PSNL 5
- Target Price
- FISI $33.00
- PSNL $8.00
- AVG Volume (30 Days)
- FISI 169.9K
- PSNL 1.7M
- Earning Date
- FISI 07-24-2025
- PSNL 08-06-2025
- Dividend Yield
- FISI 4.55%
- PSNL N/A
- EPS Growth
- FISI N/A
- PSNL N/A
- EPS
- FISI N/A
- PSNL N/A
- Revenue
- FISI $108,628,000.00
- PSNL $85,694,000.00
- Revenue This Year
- FISI $122.14
- PSNL $0.45
- Revenue Next Year
- FISI $5.87
- PSNL $25.75
- P/E Ratio
- FISI N/A
- PSNL N/A
- Revenue Growth
- FISI N/A
- PSNL 15.57
- 52 Week Low
- FISI $20.97
- PSNL $2.61
- 52 Week High
- FISI $29.79
- PSNL $7.79
- Technical
- Relative Strength Index (RSI)
- FISI 60.22
- PSNL 48.39
- Support Level
- FISI $26.60
- PSNL $6.12
- Resistance Level
- FISI $27.61
- PSNL $6.67
- Average True Range (ATR)
- FISI 0.57
- PSNL 0.48
- MACD
- FISI 0.02
- PSNL -0.14
- Stochastic Oscillator
- FISI 77.42
- PSNL 5.33
About FISI Financial Institutions Inc.
Financial Institutions Inc operates as a financial holding company, engages in the provision of a wide range of consumer and commercial banking services to individuals, municipalities, and businesses in Western and Central New York. It operates through one segment: The Banking segment which includes all of the company's retail and commercial banking operations.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.